KOL Views Preview: Fleshing out the role of Amgen's tezepelumab in severe asthma

Expectations for Amgen's severe asthma therapy tezepelumab have ebbed and flowed in recent months. The anti-TSLP mAb hit the top-line mark in the Phase III NAVIGATOR trial last November and last week's data presentation revealed an impressive reduction in exacerbations, but these were sandwiched around a miss in the Phase III SOURCE trial testing its ability to reduce oral corticosteroid (OCS) use.

To provide FirstWord readers with rapid feedback on how tezepelumab may fit into an evolving treatment paradigm, we are hosting an expert call with a key opinion leader (KOL) this week.

Key topics that will be discussed during the call include, among other things… what were the biggest question marks you had about tezepelumab coming into last week's data presentation from the NAVIGATOR trial; what stands out most about the detailed findings; how does the 56% reduction in annualised asthma exacerbation rate (AAER) versus placebo after 52 weeks stack up relative to your expectations; how impressive was tezepelumab's activity in patients with low eosinophil counts, notably the subgroups with less than 300 cells/uL and 150 cells/uL; are there any safety signals that will be worth keeping an eye on; how might tezepelumab's failure to reduce OCS use in the SOURCE trial affect its use; are you hoping to learn anything in particular from the detailed SOURCE readout, what are tezepelumab's biggest strengths and weaknesses relative to other biologics; where do you see it fitting into the treatment paradigm; how will you decide between the various biologic options; which of the biologics will tezepelumab compete most directly with and how do they compare; are there subgroups in which you would prescribe tezepelumab as first-line therapy?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the use of tezepelumab and other biologics for severe asthma.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord Pharma would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.